Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986207 + nivolumab
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986207 + nivolumab is a combination of two investigational and approved monoclonal antibodies being studied for the treatment of advanced solid tumors. BMS-986207 is an anti-TIGIT antibody that targets TIGIT, an inhibitory receptor on T cells and natural killer (NK) cells, aiming to enhance immune activation against tumors. Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor approved for several cancers, blocking the PD-1 pathway to restore T-cell function. This combination is being developed and investigated by Bristol-Myers Squibb as an immunotherapy regimen to enhance anti-tumor immune responses in patients with advanced solid or metastatic tumors[1][4][7].
- Other names
- anti-TIGIT antibody + anti-PD-1 antibody
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on BMS-986207 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986207 + nivolumab.